Jyong Biotech Ltd.
MENSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Jyong Biotech Ltd. focuses on Biotechnology services and products. Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States,. At a $134.6M market cap, Jyong Biotech Ltd. ranks as a micro-cap company within healthcare. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Market Cap
$134.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.06
EPS (Fwd)
—
ROE
—
ROA
-12.0%
Cash
$1.2M
Total Debt
$18.5M
Free CF
$4.4M
52W Change
-96.5%
Annual Financials
Cash vs Debt
Where MENS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MENS finished 9.39% below its 150-day moving average ($2.13) and 13.84% below its 200-day moving average ($2.24). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MENS overbought or oversold?
At the October 20, 2026 close, MENS's RSI(14) was 43.8, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.2M in cash, though total debt stands at $18.5M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $4.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing MENS.